Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avanos Medical ( (AVNS) ) has issued an update.
On February 25 and 26, 2026, Avanos Medical, Inc. entered into a cooperation agreement with investor Bradley L. Radoff and his affiliated foundation, resolving a potential proxy contest and securing Radoff’s withdrawal of a director nomination. Under the deal, Avanos agreed to nominate Electromed CEO James L. Cunniff and former Haemonetics CFO William P. Burke as independent directors for election at its 2026 annual meeting, and the Radoff parties accepted standstill and voting commitments through key dates ahead of the 2027 meeting, signaling a governance refresh designed to bolster operational and financial expertise on the board and align with the company’s long‑term strategy.
The company highlighted the nominees’ extensive leadership, operating and financial backgrounds in the medical technology sector, which the board expects to strengthen Avanos’s execution of its strategic priorities and enhance oversight. The arrangement underscores continued shareholder engagement around Avanos’s direction while aiming to stabilize its governance framework, with the formal slate and recommendations to be detailed in proxy materials to be filed with the U.S. Securities and Exchange Commission ahead of the 2026 shareholder vote.
The most recent analyst rating on (AVNS) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.
Spark’s Take on AVNS Stock
According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.
The score is driven primarily by mixed fundamentals: improving revenue and currently positive cash flow offset by ongoing net losses and recent free-cash-flow decline. Technicals are supportive with a clear uptrend, but momentum looks stretched. Earnings-call outlook is moderately positive with solid 2026 guidance and mitigation plans, though near-term tariffs are a meaningful margin headwind. Valuation is pressured by losses (negative P/E) and no stated dividend yield.
To see Spark’s full report on AVNS stock, click here.
More about Avanos Medical
Avanos Medical, Inc. is a U.S.-based medical technology company that develops, manufactures and markets medical device solutions aimed at helping patients return to normal life. Headquartered in Alpharetta, Georgia, it focuses on critical healthcare needs such as enteral nutrition from hospital to home and reducing opioid use in post-surgical recovery, holding leading positions across several global product categories.
Average Trading Volume: 562,413
Technical Sentiment Signal: Sell
Current Market Cap: $633.2M
For detailed information about AVNS stock, go to TipRanks’ Stock Analysis page.